Literature DB >> 25512636

Melanoma BRAF fusions--response.

Katherine E Hutchinson1, Jeffrey S Ross2, Philip J Stephens3, Vincent A Miller3, Jeffrey A Sosman4, William Pao5.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2014        PMID： 25512636      PMCID： PMC4617643          DOI： 10.1158/1078-0432.CCR-14-1152

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN： 1078-0432            Impact factor:   12.531


× No keyword cloud information.
  5 in total

1.  Kinase fusions are frequent in Spitz tumours and spitzoid melanomas.

Authors:  Thomas Wiesner; Jie He; Roman Yelensky; Rosaura Esteve-Puig; Thomas Botton; Iwei Yeh; Doron Lipson; Geoff Otto; Kristina Brennan; Rajmohan Murali; Maria Garrido; Vincent A Miller; Jeffrey S Ross; Michael F Berger; Alyssa Sparatta; Gabriele Palmedo; Lorenzo Cerroni; Klaus J Busam; Heinz Kutzner; Maureen T Cronin; Philip J Stephens; Boris C Bastian
Journal:  Nat Commun       Date:  2014       Impact factor: 14.919

2.  Paradoxical activation and RAF inhibitor resistance of BRAF protein kinase fusions characterizing pediatric astrocytomas.

Authors:  Angela J Sievert; Shih-Shan Lang; Katie L Boucher; Peter J Madsen; Erin Slaunwhite; Namrata Choudhari; Meghan Kellet; Phillip B Storm; Adam C Resnick
Journal:  Proc Natl Acad Sci U S A       Date:  2013-03-26       Impact factor: 11.205

3.  BRAF fusions define a distinct molecular subset of melanomas with potential sensitivity to MEK inhibition.

Authors:  Katherine E Hutchinson; Doron Lipson; Philip J Stephens; Geoff Otto; Brian D Lehmann; Pamela L Lyle; Cindy L Vnencak-Jones; Jeffrey S Ross; Jennifer A Pietenpol; Jeffrey A Sosman; Igor Puzanov; Vincent A Miller; William Pao
Journal:  Clin Cancer Res       Date:  2013-12-15       Impact factor: 12.531

4.  A novel SND1-BRAF fusion confers resistance to c-Met inhibitor PF-04217903 in GTL16 cells through [corrected] MAPK activation.

Authors:  Nathan V Lee; Maruja E Lira; Adam Pavlicek; Jingjing Ye; Dana Buckman; Shubha Bagrodia; Sreesha P Srinivasa; Yongjun Zhao; Samuel Aparicio; Paul A Rejto; James G Christensen; Keith A Ching
Journal:  PLoS One       Date:  2012-06-22       Impact factor: 3.240

5.  Targeted therapy by combined inhibition of the RAF and mTOR kinases in malignant spindle cell neoplasm harboring the KIAA1549-BRAF fusion protein.

Authors:  Vivek Subbiah; Shannon N Westin; Kai Wang; Dejka Araujo; Wei-Lien Wang; Vincent A Miller; Jeffrey S Ross; Phillip J Stephens; Gary A Palmer; Siraj M Ali
Journal:  J Hematol Oncol       Date:  2014-01-14       Impact factor: 17.388
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.